The incredibly high profit margins and perfect balance sheet as well as energy exposure that we didn't have in the MaM ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

New Jersey residents spent more than 42 other states on health care in America, with Type 2 diabetes, hip, knee and back injuries and dental care the conditions the most responsible for driving up ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Move over, chips and cookies – snacking is getting a GLP-1-era makeover. A recent Cornell University and Numerator study found households with at least one user of GLP-1 – medications like ...

While Ozempic has helped thousands achieve significant weight reduction, many are reporting an unwelcome side effect: thinning hair and increased shedding that appears months into treatment.

Hims & Hers Health (HIMS) will keep offering compounded versions of Ozempic and Wegovy tweaked to individual prescriptions, while some pharmacies making the GLP-1 drug copycats will continue ...

Plenty of folks have been using GLP-1s — generic knockoffs of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately. But those folks could be in ...

Though reports of Ozempic butt and Ozempic face have made news, Ozempic side effects typically involve weight loss, nausea, and stomach discomfort. But, does Ozempic cause hair loss? Meet the ...

The maximum dose for Ozempic is 2 mg once per week. The following dosing chart shows how your doctor may adjust your dosage of Ozempic. Dosage strength Starting dose Maintenance dose Dosing ...

On Monday, Novo Nordisk A/S (NYSE:NVO) returned to full membership of the Association of the British Pharmaceutical Industry (ABPI) following extensive audits of the Wegovy maker's compliance ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...